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1.1 Discovery and structure of lantibiotics
Just before the discovery of penicillin by Fleming, reports
appeared in the literature that described potent antimicrobial
substances produced by lactic acid bacteria.1,2 In those days the
nature of the inhibitory compound was not yet elucidated, but in
retrospect it seems likely that the inhibitory activity was caused
by the production of the special class of peptides that forms the
subject of this review. It was found that many Gram-positive
bacteria secrete compounds which are specifically active
against a wide range of other Gram-positive bacteria.3–5 This
characteristic made these compounds attractive candidates for
application in either food preservation, e.g. by preventing
spoilage or by inhibiting pathogens, or for pharmaceutical use,
e.g. to prevent or fight infections in humans or animals. These
prospects greatly stimulated more detailed research to elucidate
the molecular structures of the antimicrobial compounds.
Pioneering work by Gross and Morell in the late sixties and
early seventies showed for the first time the unique structural
features of the class of bacterial antimicrobial peptides that are
called lantibiotics today.6,7 These small peptides ( < 4 kDa) are
characterized by their high content of amino acid residues that
are uncommon in nature, i.e. the thioether bridged amino acid
residues lanthionine and 3-methyllanthionine, and the un-
saturated amino acid residues dehydroalanine and dehy-
drobutyrine (Fig. 1). Due to the presence of these modified
residues, the elucidation of the primary structure of these
peptides by conventional Edman degradation techniques was
delayed. Gross and Morrell succeeded in the elucidation of the
first primary structures of lantibiotics, i.e. that of nisin,6
produced by Lactococcus lactis, and that of subtilin,7 produced
by Bacillus subtilis. These 34- and 32-amino acid residue
peptides, respectively, showed the presence of three dehydrated
residues, i.e. dehydroalanine and dehydrobutyrine, and five
thioether bridges, forming rings A, B, C, D and E. Fig. 2 shows
the primary structures of nisin and subtilin and those of several
other well known lantibiotics.8 All peptides share the common
feature of containing lanthionine residues. In addition, a number
of other unusual residues is found, which are mostly modified
forms of serine, threonine or cysteine residues. The C-terminal
Cys-residue of epidermin is oxidized and decarboxylated,
resulting in 2-aminovinyl-d-cysteine (AviCys).8 Lactocin S
contains d-Ala residues, which arise from modification of Dha
residues. Dha or Dhb residues that are present at position 1 are
unstable and undergo additional modifications, as has been
found in the lantibiotics epilancin K7, Pep5, epicidin 280 and
lactocin S.8 It should be noted that for some lantibiotics the
experimental proof for their structure is not complete and for
those lantibiotics the proposed primary structure is indicated.
It was already speculated in the seventies that these peptides
could be derived from ribosomally synthesized precursor
peptides, which had been posttranslationally modified. In the
eighties total chemical synthesis of the lantibiotics subtilin and
epidermin was achieved by highly specialized organic chemists
from Japan, who were also the first to produce fragments and
site-specifically altered species of lantibiotics.9 Many years
later these compounds turned out to be extremely valuable for
structure–function relationship studies and even for gene
regulation studies.10 The first 3D-structures of specific lanti-
biotics in aqueous solution or in DMSO were determined in the
late eighties.11–15 The structure of nisin A was studied in most
detail (Fig. 3). The NMR structures showed that there was not
a well-defined overall fold of this peptide, but that it is quite
flexible in solution. The molecule clearly is amphipathic and the
structures of the rings B, D and E are well defined as essentially
being beta-turns fixed by a thioether bond. Between rings C and
D a flexible hinge region was identified, which could be
important for the membrane insertion properties of the mole-
cule.15
Fig. 1 The structure of some unusual amino acid residues found in
lantibiotics. The thiol of Cys-residues attacks the double bond of
dehydroalanine or dehydrobutyrine residues.
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Based on their chemical structures and their antimicrobial
activities the lantibiotics are subdivided into type A and type B
lantibiotics.16 Type-A lantibiotics, which are the subject of this
overview, are elongated peptides, which have a net positive
charge. They exert their activity by permeabilisation of the
cytoplasmic membrane of target cells. Type-B lantibiotics are
smaller, globular and have a low net positive charge. Their
antimicrobial activity is related to the inhibition of specific
enzymes. Representatives of this group are mersacidin, dur-
amycin, actagardin and cinnamycin. During the last years the
number of newly discovered lantibiotics has increased rapidly.
Table 1 lists several recently discovered lantibiotics that were
shown to contain lanthionine residues, but of which the
structure is still unknown. Cytolysin, produced by Enterococcus
faecalis17 and the recently identified bacteriocins lacticin
314718 and staphylococcin C5519 are unique in being two-
component lantibiotics. For antimicrobial activity of these
lantibiotics, both components are required. In the gene cluster of
these lantibiotics two structural genes are present, both
encoding a precursor molecule. Both components are post-
translationally modified and secreted independently. Salivaricin
G32 is considered to be a natural variant of streptococcin A-
FF22, in which the residue Lys-2 is absent.20 The recently
discovered lantibiotic sublancin 168, produced by Bacillus
subtilis is the only lantibiotic species known so far that contains
two disulfide bridges next to a thioether bridge.22
A great advancement in the study of lantibiotics was the
publication of the first gene encoding the precursor of a
Fig. 2 The primary structure of some type-A lantibiotics. Ala-S-Ala: lanthionine, Abu-S-Ala: b-methyllanthionine, Dha: dehydroalanine, Dhb:
dehydrobutyrine. Residues marked with an asterisk are in the d-configuration. For those lantibiotics of which complete structural information is not available,
the proposed bridging pattern is indicated.
Fig. 3 One of the 3-dimensional structures of nisin A as determined by van de Ven et al.15 The peptide backbone is indicated in liquorice. The side-chains
(non-hydrogen atoms) are represented as ball–stick models. The sulfurs of the lanthionine residues are indicated as spheres.
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lantibiotic, i.e. epidermin produced by Stapylococcus epidermi-
dis.23 The encoded precursor sequence shared high similarity in
its C-terminal half with the residues in the known primary
structure of epidermin, except for the presence of several Ser,
Thr and Cys residues, that were either Dha, Dhb, (3-methyl)lan-
thionine or S-aminovinyl-d-cysteine residues in the active
epidermin. This finding unambiguously demonstrated that a
mature lantibiotic is ribosomally synthesized as an unmodified
precursor protein, which is probably enzymatically converted
into the modified precursor. At a certain stage, in several cases
shortly after translocation across the bacterial membrane, the
leader peptide is removed, yielding the active antimicrobial
peptide.
After the finding that lantibiotics are ribosomally synthesized
peptides a wealth of novel information was generated in the late
eighties and early nineties by sequencing of several gene
clusters involved in the biosynthesis of various lantibiotics,
among which the gene clusters of nisin A24 and Z (these
lantibiotics differ only in residue 27, being His and Asn,
respectively),25 subtilin,26 Pep5,27 gallidermin,28 streptococcin
A-FF22,29 lacticin 48130 and epilancin K7.31 Comparison of the
lantibiotic gene clusters generated the overall picture that a
lantibiotic is first produced as an unmodified precursor peptide
that is intracellularly converted into a modified precursor
peptide by the action of one or two dedicated enzymes,
commonly denoted as LanB, LanC (two enzymes) or LanM
(one enzyme). Subsequently, the modified precursor protein is
secreted and processed by dedicated LanT and LanP proteins, or
one protein with a dual function. The producing cells protect
themselves against the antimicrobial activity through specific
immunity proteins (LanI, LanF, LanE, LanG). More recently it
was established in some cases that the expression of the genes
involved in the biosynthesis is autoregulated by the mature
lantibiotic, through the two regulatory proteins LanR and
LanK.10
The broad application possibilities for lantibiotics have
greatly stimulated further research into the details of the
complex biosynthesis, mode of regulation, and mechanism of
self-protection of the cell (immunity). Moreover, it became
clear that it is of crucial importance to understand the
mechanism of action of lantibiotics in molecular detail. In this
review the latest developments in all these areas will be
discussed, with special emphasis on recent advances brought
about by the use of protein engineering techniques and
membrane biochemistry to elucidate the structure–function
relationship of lantibiotics (exemplified by nisin). Last but not
least, the broadening area of applications and new possibilities
for use that have arisen from fundamental research on
lantibiotics will be highlighted in the last section. To keep this
review concise we have chosen to highlight mainly research on
a limited number of type-A lantibiotics, which are relatively
well characterized, i.e. nisin, subtilin, epidermin and Pep5.
From these we will highlight in most cases nisin as the main
example, because this lantibiotic has been characterized in most
detail. In particular cases, we have also included additional
information on other lantibiotics when these display one or
more unique features not encountered in the ones mentioned
above. Without any doubt the study of various other lantibiotics,
e.g. cytolysin LL/LS,17 mutacin,32 carnocin UI49,33 epilancin
K7,29 salivaricin A,34 variacin,35 lacticin 481,36 streptococcin
A-FF22,37 sublancin,22 epicidin 280,38 lactocin S39 and lacticin
314718 also generated many new insights in lantibiotic function,
biosynthesis and application. However, in view of the limited
space available these species will not be discussed here in any
detail. For this, the reader is referred to some excellent and
elaborate reviews on lantibiotics that have been published
previously16,40,41 and the more recent original research papers
that are mentioned above.
2 Biosynthesis of lantibiotics
2.1 Organization of the gene clusters
The genes involved in biosynthesis of the model lantibiotic
nisin are located on a 70 kb conjugative transposon,42 which
also contains the genetic information for sucrose metabolism.
The first gene of the nisin gene cluster, nisA, encodes the 57
amino acid nisin precursor, consisting of a N-terminal leader
sequence followed by the propeptide, from which nisin A is
matured. The structural gene is followed by ten other genes i.e.
nisB, nisT, nisC, nisI, nisP, nisR, nisK, nisF, nisE, nisG,43
encoding regulatory proteins, proteases, transport proteins and
immunity proteins (Fig. 4). The proteins that are encoded by
these genes have been found to be homologous to gene products
of the gene clusters of other lantibiotics, such as those of
subtilin, epidermin and Pep5. Not all of the mentioned genes
have been detected in all gene clusters, so far. Besides, there is
no uniform order of the genes in the individual gene clusters.
For an overview of the organization of the various gene clusters
the reader is referred to Siezen et al.44
2.2 Modification and transport
The gene clusters for nisin,45 subtilin,46 epidermin,47 Pep548
and epicidin 28038 all contain the genes lanB and lanC. These
genes do not display significant homology to known genes in
sequence databases and their function is not completely
Table 1 Type-A lantibiotics that have been isolated and were shown to
contain (b-methyl)lanthionine residues. The bridging pattern of the
lanthionine residues is not known yet
Lantibiotic Mass/Da Producer organism Ref.
Cytolysin LL 4164 Enterococcus faecalis 17
2631
Lacticin 3147 2852 Lactococcus lactis 18
3323
Streptococcin C55 3339 Staphylococcus aureus 19
2993
Streptococcin A-FF22 2794 Streptococcus pyogenes 37
Carnocin 4635 Carnobacterium piscicola 33
Variacin 2659 Micrococcus varians 35
Salivaricin G-32 2667 Streptococcus salivarius 20
Sublancin 168 3877 Bacillus subtilis 22
Fig. 4 Model for the biosynthesis of nisin. The nisin precursor is modified
by the putative enzymes NisB and NisC and translocated across the
membrane by the exporter NisT. The precursor is extracellularly processed
by NisP, resulting in the release of mature nisin. NisK senses the presence
of nisin in the medium and autophosphorylates. The phosphate-group is
transferred to NisR, which activates transcription of the genes nisABTCIP
and nisFEG. NisI, F, E, and G protect the cell from the bacteriocidal activity
of nisin. P: promoter region, P*: nisin-regulated promoters.
Nat. Prod. Rep., 1999, 16, 575–587 577
understood yet. It has been shown that both genes are essential
for the production of lantibiotics, since their disruption results in
cessation of lantibiotic biosynthesis.45,46,49 Most likely, LanB
and LanC are involved in post-translational modification of the
lantibiotics, involving the formation of dehydrated residues and
interaction of these residues with the sulfhydryl group of a
nearby Cys-residue to form lanthionine residues. The LanB
proteins, generally around 1000 amino acid residues in size, are
the putative enzymes that catalyze dehydration of the Ser and
Thr residues in the propeptide domain of the prelantibiotic.
LanC proteins are all about 400 amino acid residues long.
Deletion of the pepC gene in Staphylococcus epidermidis
resulted in production of incorrectly modified Pep5 fragments,
that contained only one of three expected lanthionine residues.47
This suggested that PepC is the thioether-forming protein.
Investigations on the proteins SpaB48 and EpiB50 revealed that
these proteins are membrane-associated, suggesting that lanti-
biotic biosynthesis occurs at the cytoplasmic membrane.
Moreover, by use of the yeast two-hybrid system and co-
immunoprecipitation techniques, it was shown that nisin51 and
subtilin52 precursor peptides are processed by a multimeric
protein complex located at the cytoplasmic membrane, consist-
ing of LanB, LanC and LanT proteins.
In the cyl, las, lct and mut gene clusters, for biosynthesis of
cytolysin, lacticin 481, lacticin S and mutacin II, respectively,
LanB is missing. Instead a LanM protein is found,17,53,54 from
which the C-terminal part is homologous to LanC proteins.44
Possibly, LanM is able to catalyze both the reactions assumed to
be catalysed by LanB and LanC. The epidermin-gene cluster is
unique in that it contains the gene epiD, encoding a 181 amino
acid protein that is also involved in post-translational modifica-
tion of epidermin. To identify its function, EpiD was purified
from Staphylococcus epidermidis and incubated in vitro with
epidermin precursor peptide.55 The results showed that EpiD is
a flavoenzyme that catalyzes the oxidative decarboxylation of
the C-terminal Cys-residues of epidermin, a modification that is
only found in epidermin and its natural variant gallidermin.
Another experimental approach in which a variant epiA gene
encoding His-tag-labelled epidermin was co-expressed with
epiD established this role of EpiD.56 In the gene cluster of
epicidin 280, which is produced by Staphylococcus epidermi-
dis, an additional gene was found, designated epiO.38 Since this
gene has similarity to a family of oxidoreductases, it most likely
codes for an enzyme that catalyzes the modification of the N-
terminal residue of epicidin 280.
All known lantibiotic gene clusters contain a lanT gene,
which encodes a protein that is involved in transport of the
lantibiotic precursor across the cellular membrane to outside the
cell. It was first shown for subtilin that disruption of the gene
spaT resulted in intracellular accumulation of subtilin.46 A
number of transport protein-encoding genes have now been
identified in several of the lantibiotic gene clusters, including
those for nisin,45,57 lacticin 481,53 lactocin S38 and recently for
lacticin 3147.18 It should be noted that the transport gene in the
cyl gene cluster is designated cylB.17 The LanT proteins share
homology with a large family of transport proteins, charac-
terized by the presence of a cytoplasmic ATP-binding domain
and a membrane spanning domain. For all lantibiotic trans-
porters, with the exception of EpiT, both domains are present in
one protein, of about 600 amino acid residues in size. The gene
encoding EpiT is incomplete and it seems not to be required for
transport of epidermin in Staphylococcus epidermidis.37 Possi-
bly, transporter proteins of the host replace its function.
Introduction of gdmT, the transporter gene of the related
lantibiotic gallidermin into an epidermin producing strain
strongly increased production yields. The epi and gdm gene
clusters also contain a lanH gene, encoding a protein of about
330 amino acids containing several putative transmembrane
sections. GdmH is assumed to be involved in secretion of
gallidermin, in cooperation with GdmT.58
2.3 Processing of precursor peptides
The last step in the biosynthesis of lantibiotics is the removal of
the leader peptide from the lantibiotic precursor. In the gene
clusters for the lantibiotics nisin,59 epidermin,47 Pep5,48
epilancin K7,60 lacticin S,39 cytolysin17 and epicidin 28038 a
lanP gene was found encoding a subtilisin-like protease. The
location at which processing of the leader peptide occurs, varies
with the lantibiotic. NisP, responsible for cleavage of the nisin
precursor is anchored to the cellular membrane at the outside of
the host cell.59 EpiP and CylP are also transported to the outside
of the cell, but appear to lack a membrane anchor.44 In contrast,
PepP, ElkP and LasP were reported to act in the cytoplasm of
cells, possibly in association with LanB, C and T.44 Cleavage of
lacticin 481 occurs by the protein LctT, which displays a dual
function since it is responsible for proteolytic cleavage as well
as secretion of the lantibiotic.61 In contrast to the gene clusters
discussed above, the spa gene cluster does not contain a gene
encoding a peptidase, and it is assumed that processing of
subtilin occurs by a general serine protease of the host Bacillus
subtilis.44
The function of the leader peptide is unclear. The fully
modified lantibiotic precursor is almost inactive, and it has been
suggested that the leader sequence is of importance to keep the
lantibiotic in an inactive state, to protect the producer cell from
its activity.16 However, this does not hold for those lantibiotics
that are cleaved intracellularly. NMR studies on the nisin
precursor have demonstrated that the residues Ile1-Ala19 of the
nisin precursor interact differently with membrane-mimicking
micelles than the corresponding part of mature nisin.62 These
results indicate that the low in vivo activity of the precursor is
caused by a less efficient insertion of the peptide into a
membrane.62 The leader peptide might alternatively, or addi-
tionally, play a role in modification and excretion of the peptide,
for instance by targeting the unmodified precursor to the
modification and secretion machinery. This assumption was
strengthened by the observation that specific mutations in the
leader sequences of nisin63 and Pep564 strongly affected the
production level of the lantibiotics. Obviously, a defined leader
sequence is of importance for optimal biosynthesis of the
lantibiotic.
2.4 Immunity of producer organisms
One of the most intriguing questions in lantibiotic production
concerns the mechanism of self-protection. Obviously, without
efficient ways to protect themselves from the pore-forming
activity of the peptides, the producing cells would be suicidal. In
all gene clusters studied so far small (50–70 AA) or medium-
sized (160–250 AA) hydrophobic proteins (LanI) are encoded
that are attached to the outside of the membrane and are
involved in the immunity process. So far, LanI proteins have
been found in nisin A45,65 and Z,66 subtilin,67 Pep568 and
epicidin 28038 producing cells. Possibly, these molecules play a
role in the recognition of the active lantibiotic present at the
outside of the cell, either directly from solution or upon
adsorption to the membrane. Overexpression of LanI proteins in
cells that do not possess the lantibiotic biosynthesis machinery
only yields very low protection levels (1–4%) against the
corresponding lantibiotic.45,65,69 An in-frame disruption of nisI
in Lactococcus lactis yielded a strain that could still produce
nisin, albeit to levels five times lower than wild-type,70 which
suggests that the immunity level could be the first limiting
factor in reaching high production levels. These results already
indicate that additional factors are involved in the acquirement
of full self-protection.
In several lantibiotic gene clusters three other proteins are
encoded, named LanF, LanE and LanG. The LanFEG proteins
belong to the group of ABC transporters, where LanF contains
the intracellular ATP-binding domain and LanEG the mem-
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brane-spanning subunits. The genes lanFEG have been found in
the gene clusters for nisin,71 subtilin,67 lacticin 481,72 epi-
dermin73 and lacticin 3147.18 It is tempting to speculate that
these proteins have a function in the removal of the correspond-
ing lantibiotic at a certain stage of its membrane interaction.
Expression of the LanFEG proteins, without LanI, yields a
significant level of immunity although it remains below the
wild-type level.74 The synergistic function of all immunity
proteins could thus reside in the first recognition and binding or
‘immobilization’ of the lantibiotic in the membrane by NisI,
followed by active removal, in which the LanFEG proteins are
involved. It cannot be excluded, however, that also other
proteins encoded in the lantibiotic gene clusters display a
synergistic effect in the immunity mechanism, for instance by
being involved in a multi-protein complex that spans the
membrane. Candidates to be involved in such a complex are
LanBTC proteins, which have already been shown to form a
membrane associated complex.51,52
Interestingly, in some cases, e.g. nisin and subtilin produc-
tion, the expression of immunity genes is also regulated by the
concentration of the lantibiotic in the medium (see also section
2.5), which means that by sensing low (subinhibitory) amounts
of the antimicrobial peptide in the medium, cells can rapidly
increase their immunity level, concomitant with or even faster
than the biosynthesis rate.75 The challenge still exists to unravel
the complete mechanism of immunity at the molecular level, the
understanding of which could in the end result in engineering
increased immunity and possibly increased production levels of
lantibiotics.
2.5 Regulation of biosynthesis
In 1995 it was reported that apart from displaying a strong
antimicrobial activity, the lantibiotic nisin also plays an
important role in the regulation of its own biosynthesis.10 In fact
nisin can be regarded as a peptide pheromone which is sensed
by the histidine kinase NisK, which resides at the outer side of
the membrane, probably by direct protein–peptide interaction.
By analogy with other known two-component regulatory
systems76–78 NisK will autophosphorylate at a specific histidine
residue when it senses a certain nisin concentration in the
medium and subsequently transfer the phosphate moiety to the
response regulator NisR. The response regulator is assumed to
get phosphorylated at a specific Asp residue, which is supposed
to trigger its binding to two regulated promoters in the nisin
gene cluster, i.e. the nisA and the nisF promoter, thereby
activating transcription of the structural gene nisA and the
downstream genes nisBTCIP by limited readthrough from nisA,
and the genes nisFEG located at the end of the gene cluster.10,75
The regulatory genes nisRK themselves are transcribed from
their own promoter which is assumed to be not dependent on
nisin induction.75 Although not all molecular details have been
unraveled yet, it is clear that this autoregulatory process
resembles the quorum-sensing phenomenon found in several
Gram-negative bacteria, for which the bioluminescence pheno-
type of Photobacterium fischeri is the paradigm.78,79
The transcription from the nisA and nisF promoter in the nisin
gene cluster is directly related to the concentration of nisin in the
medium. This property is extremely useful for the development
of controlled gene expression systems, since a linear dose–
response for the expression of target genes is highly desirable in
industrially relevant production organisms. Especially when
toxic gene products should be produced, the nisin-controlled
expression (NICE) system is ideally suited, since the nisA
promoter is tightly shut off in the uninduced state.80–82
Moreover, very high expression levels of up to 60% of total
intracellular protein can be reached in Lactococcus lactis. The
NICE system has also been succesfully implemented in some
heterologous hosts like the lactic acid bacteria Leuconostoc
lactis and Lactobacillus helveticus83 and the Gram-positive
bacteria Streptococcus pyogenes, Bacillus subtilis and Enter-
ococcus faecalis.84
Since in many other lantibiotic and non-lantibiotic gene
clusters the counterparts of the two-component regulatory
proteins NisR and NisK are found, it is reasonable to assume
that also in these cases an autoregulatory process takes place. In
fact for the production of several non-lantibiotic antimicrobial
peptides, e.g. carnocin, plantaricin and sakacin the peptide
pheromone concept has been shown to be valid.78,85–87 In the
case of subtilin production the autoregulatory process has been
shown to be very similar to the nisin case, because the spaB,
spaI and SpaS promoters could be activated by subtilin in the
medium.88 Knock-outs of spaRK and nisRK have been shown to
be detrimental for lantibiotic production10,88,89 An exception to
the general rule is found in the case of epidermin, since in that
biosynthetic gene cluster only the response regulator encoding
EpiQ was found to be present.90 Possibly, a high expression
level of only the response regulator results in effective
expression of the target genes, probably because this protein
will be phosphorylated in an aspecific way. Also by over-
expression of nisR in a strain lacking nisK, efficient transcrip-
tion from the nisA promoter was observed.59
Both inducer and sensor engineering have been used to study
the molecular interaction between these molecules. First, it was
shown that variants and fragments of nisin were able to act as
inducer with variable efficiencies and that their induction
capacity was unrelated to their antimicrobial activity, demon-
strating that the mechanisms for induction and pore formation
are different10,91,92 In a recent study a plasmid containing the
reporter gene gusA under control of the nisA promoter was
introduced in a strain containing the nisR gene integrated on the
chromosome. Introduction of a nisK expressing plasmid in this
strain resulted in a fully functional nisin induction system.
Surprisingly, also introduction of spaK, combined with subtilin
as inducer, led to a functional signal transduction, showing that
cross-talk between SpaK and NisR occurs, albeit with decreased
efficiency. In an extension of this study hybrids of NisK and
SpaK were constructed. It was demonstrated that the subdomain
needed for inducer interaction is located in the N-terminal
domain of the sensor protein and includes at least both
transmembrane domains and the external loop.88 A better
understanding of these interactions will open the way to the
rational design of more effective sensors and perhaps even to
sensors with a loosened specificity for the inducer molecule.
Undoubtedly, in the coming years the autoregulatory processes
found to occur in many lantibiotic biosynthesis processes will
yield valuable spin-off for a variety of industrial applications,
e.g. increased production levels, development of novel bio-
sensors and improved controlled gene expression systems.
3 Protein engineering of lantibiotics
3.1 Expression systems for modified lantibiotic
structural genes
Knowledge of the organisation of the gene clusters and the
biosynthesis pathways of lantibiotics enabled the development
of various expression systems for lantibiotic structural genes.
This has opened up possibilities to produce engineered
lantibiotic molecules with altered biological properties. Differ-
ent strategies have been described for the production of mutant
species. In the first report a plasmid-encoded mutant copy of the
nisin structural gene is introduced in a nisin-producing strain,
which results in simultaneous production of wild-type nisin and
the mutant species.93 In this way, the biosynthesis machinery
was assured to be functional. However, this approach had the
disadvantage that the mutant species could not always be
separated from the wild-type easily. Therefore, a common
approach was developed for nisin,94 Pep595 epidermin and
gallidermin96 which involves the introduction of a disruption in
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the structural gene of the lantibiotic gene cluster, located either
on the chromosome of the host-strain, or in case of Pep5, on a
plasmid. The deficient gene is complemented with a plasmid-
encoded variant of the structural gene. The plasmid-encoded
gene is easily manipulated by molecular techniques and can be
expressed under control of a strong promotor, independent of
the biosynthetic genes. Alternatively, gene replacement expres-
sion systems were developed for nisin A,10,97 subtilin98
gallidermin99 and recently for mutacin II,100 in which the
chromosomally located structural gene was replaced by a
mutant copy of this gene. The latter strategy has the advantage
that the balance between the expression of the structural gene
and the biosynthesis genes is maintained, because the variant
gene is expressed at its natural locus.
The approaches in which only a mutant copy of the structural
gene is expressed by the host strain ensure production of solely
the engineered lantibiotic molecule by the bacteria, which
facilitates purification of the mutant peptide. Problems may
arise when the produced mutant lantibiotic has lost its capacity
to act as signaling molecule, due to the introduced mutation.10
For many mutant nisin species it has been reported that their
signaling capacity was reduced, probably due to a disturbed
interaction with the sensor histidine kinase NisK.10 As a
consequence, the transcription of the biosynthetic and immunity
genes of the gene cluster is not fully activated, resulting in a low
production level of the engineered lantibiotic. Addition of low
amounts of wild-type nisin to the growth medium of the
expression strain stimulated the production of these mutants.10
For production of some mutant species it appeared to be
essential to add external nisin, because production of these
species could otherwise not be detected.92
3.2 Site-directed mutants of lantibiotics
In the past decade, a large variety of engineered lantibiotic
molecules has been produced and characterised. The physical,
biochemical and biological properties of the more than 40
lantibiotic mutants that were known up till 1994, as well as the
expression systems that were used to obtain these variants, are
discussed in detail in an overview by Kuipers et al.101 Despite
the well-developed expression systems for the different lanti-
biotics, it appears that the number of succesful mutations one
can apply in these peptides is limited. Many designed mutants
could not be produced, probably due to disturbed interaction of
the peptides with biosynthetic enzymes or the secretion
machinery. In particular, a strongly reduced production level
was obtained for lantibiotics in which residues were modified
that are involved in thioether formation.101 It was concluded at
that time that a correct formation of all thioether residues is of
importance for the completion of biosynthesis and secretion of
lantibiotics. Nevertheless, several lantibiotic mutants have been
isolated in which thioether residues were substituted or deleted.
Characterisation of these mutants provided insight into the
importance of the unusual lanthionine residues of lantibiotics.
Two mutants of Pep5 were purified in which cysteine residues
were replaced by alanines, resulting in peptides that were
devoid of either ring B or C. These mutant peptides were
produced as a mixture of incorrectly modified peptides as well
as degradation products.102 Furthermore, a Pep5 mutant was
generated that contained a novel thioether ring, due to
interaction of an introduced Cys-residue with the naturally
occurring Dhb-16. The production level as well as the biological
activity of all these ring-mutants was strongly reduced,
indicating that the presence of the lanthionine rings in
lantibiotics is of importance for antimicrobial activity as well as
recognition by the proteins involved in biosynthesis and
secretion. Furthermore, it was shown that deletion of a
lanthionine ring resulted in increased susceptibility of Pep5 for
proteolytic degradation.102 Recently, mutants of mutacin II
were isolated in which each of the three Cys-residues was
replaced by an Ala, each time resulting in deletion of one of the
three thioether rings.100 The production level of these mutacin II
variants, as well as their capacity to exert antimicrobial activity
against Streptococcus sobrinus was very low. Introduction of a
Cys-residue on position 13 of nisin Z resulted in the formation
of a nisin analog that contains a disulfide bond in ring C, instead
of the usual thioether bond. NMR analysis of this mutant
revealed that the structure of this mutant was similar to the wild-
type peptide, with the exception of ring C. The peptide exhibited
less than 1% of the wild-type activity, indicating that the thio-
ether ring C plays a profound role in antimicrobial activity.103
Recently, cysteine-scanning mutagenesis was applied to the
antimicrobial peptide nisin, for the purpose of the production of
nisin analogs that are suitable for chemical modification with
thiol-specific probes. For 8 Cys-mutants of nisin a lack of
production was observed. Nevertheless, two Cys-mutants of
nisin Z, i.e. S5C and M17C nisin Z, could be succesfully
isolated, by maintaining reducing conditions during the produc-
tion and purification procedure. In view of the possibilities to
chemically modify Cys-residues, these results significantly
expand the perspectives of protein engineering in the lantibiotic
field.103
Of great interest in the engineering of lantibiotics is the
possibility to design new peptides that have improved activity
against specific undesirable microorganisms, and therefore
could find commercial applications. Up till now, only a few
mutants, such as T2S nisin Z, M17Q/G18T nisin Z and L6V
gallidermin, displayed higher antimicrobial activity towards
some target strains.101 A difficulty of the rational design of
species that have increased bacteriocidal activity towards
specific strains is the fact that the mechanism of action of
lantibiotics is not yet fully understood. For this reason, research
to obtain better insight in the mode of action of lantibiotics has
gained much interest. Several mutants of nisin were designed
especially for the use as a research tool in mechanistic studies
(Fig. 5). The introduction of specific markers, such as
fluorescent labels, radioactive labels, tags, or charged residues
in nisin, has made it possible to study the interaction of the
peptide with the cytoplasmic membrane of target bacteria. How
these modifications contributed to a better understanding of the
mode of action of lantibiotics will be discussed in the next
section.
4 Mode of action of lantibiotics
4.1 Bacteriocidal activity towards Gram-positive
bacteria
Type A lantibiotics exert bacteriocidal activity towards a broad
range of Gram-positive bacterial strains, including streptococci,
bacilli, listeriae, clostridia and staphylococci. The antibacterial
effect is strong: the addition of nM concentrations of a
lantibiotic is sufficient to kill bacterial cells. In contrast, other
well-known antibacterial compounds, such as melittin, magai-
nin or cecropin, are active in mM concentrations. Fungal cells,
yeast cells or human cells are very insensitive to lantibiotics,
even when treated with mM concentrations of the peptides.104
In general, Gram-negative bacteria are also insensitive to
lantibiotics. It has been shown that their outer membrane
functions as a barrier for the lantibiotics. When the outer
membrane of the Gram-negative strains Escherichia coli104 or
Salmonella species105 was weakened by treatment with EDTA
or osmotic shock, the susceptibility of the cells towards nisin or
Pep5 strongly increased.
The primary target for the activity of the lantibiotics appears
to be the bacterial cytoplasmic membrane. The peptides
interfere with the membrane function of sensitive cells by
increasing the permeability of the bilayer for small molecules
and disrupting the membrane potential, resulting in cell death.
Within several minutes, the lantibiotics induce the release of
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ions, small molecules and ATP from sensitive bacterial cells.106
The efflux of high-molecular-weight compounds ( > 500 Da)
was not observed,107 indicating that lantibiotics do not com-
pletely disrupt the barrier function of the membrane, as
detergents do. Also, other mechanisms could be involved in
their biological activity, since it has been reported that
lantibiotics also inhibit outgrowth of bacterial spores,108
activate autolytic enzymes109 and might inhibit cell wall
biosynthesis.110 However, these mechanisms seem to be
secondary effects, since these processes are relatively slow and
require relatively high concentrations of lantibiotics.
Since the lantibiotics act on the bacterial cytoplasmic
membrane, they first have to pass the bacterial cell wall. Many
non-lantibiotic bacteriocins, such as lactococcin111 appear to
interact with membrane-associated receptor proteins, prior to
their membrane perturbing activity. In contrast, a specific
proteinaceous receptor for lantibiotic species on the outer
surface of bacteria has not been found so far. Also, the fact that
lantibiotics are able to permeabilize lipid vesicles implies that a
specific receptor is not essential for activity. In general, it is
assumed that lantibiotics reach the membrane by diffusion
through the peptidoglycan layer of Gram-positive bacteria.
Recently, it was reported that lipid-bound peptidoglycan
precursors play a role in efficient pore-formation by lanti-
biotics.112 The presence of this membrane-bound precursor in
liposomes substantially increased the susceptibility of the
liposomes to nisin and epidermin, but not to Pep5 or epilancin
K7. It was postulated that lipid II, which is present at the outer
surface of Gram-positive bacteria, serves as a docking molecule
for nisin and epidermin, facilitating specific binding to the
bacterial membrane. Additionally, the interaction with lipid II
could promote the pore-forming process, by facilitating the
insertion of the peptides into a conducting state. The concept
that nisin and epidermin specifically interact with the mem-
brane-bound lipid II, prior to membrane-disruption is very
novel. The molecular interaction and its role in the mechanism
of pore formation has to be investigated in more detail.
Furthermore, it remains to be investigated whether the use of an
integral membrane compound as a docking molecule for
specific binding to target bacteria is a general phenomenon for
type-A lantibiotics.
To understand the interaction of lantibiotics with the
cytoplasmic membrane at the molecular level, the interaction of
the peptides with various membrane-mimicking systems, such
as lipid monolayers, liposomes, black lipid membranes and
SDS-micelles was studied. From these studies a general picture
of the membrane interaction of lantibiotics has emerged, in
which the following steps can be distinguished; 1) binding of
the peptide to the membrane, 2) insertion of the peptide into the
membrane, 3) membrane permeabilisation. The mechanism of
these steps will be discussed for the prototype lantibiotic
nisin.
4.2 Binding to membranes
The first step in the mechanism of action of nisin is considered
to be the binding of the peptide to the cytoplasmic membrane of
target bacteria. Electrostatic interactions between the cationic
lantibiotic and negatively charged phospholipids appear to be
involved in this initial peptide–membrane interaction.113–115
Binding studies of nisin using fluorescently labeled phospho-
lipids established that nisin tightly interacts with membranes
containing the negatively charged lipid phosphatidylglycerol,
and has little affinity for zwitterionic lipids.107 The binding
affinity was maximal on lipid vesicles containing > 60%
negatively charged phospholipids.114 Along with these observa-
tions, it should be noted that the cytoplasmic membrane of
Gram-positive bacteria generally contains a high content of
negatively charged lipids, such as phosphatidylglycerol and
cardiolipin, while Gram-negative bacteria, yeast cells and
human cells generally contain primarily zwitterionic lipids, and
less negatively charged lipids in their membrane. This has led to
the suggestion that negatively charged phospholipids, most
likely phosphatidylglycerol, might form binding sites for
nisin.114 On the other hand, the susceptibility of bacterial
strains, or strains within one species, varies greatly, more than
one would expect on the basis of a pore formation model for
which the only prerequisite is the presence of anionic lipids. It
has been suggested that differences in the accessibility of the
lipid II molecule in bacterial strains could explain this
phenomenon.112
The C-terminal region of nisin was shown to play a dominant
role in the membrane-binding step of nisin.114 This part of the
molecule contains 4 out of the 6 positively charged residues of
nisin A (Lys-22, His-27, His-31, Lys-34), which are likely to be
involved in ionic interactions with membrane phospholipids.
The introduction of a negatively charged glutamic acid residue
in the C-terminus of nisin Z severely reduced the affinity of the
peptide for negatively charged phospholipids, indicating that
the negative charge interferes with binding to these lipids.
Concomitantly, the antimicrobial activity of this nisin analog
towards various indicator strains was strongly reduced.92
Removal of the C-terminal part of nisin, as in the peptide
fragments nisin1-12, resulted in almost complete loss of
activity.10,115 This fragment of nisin could be isolated after
prolonged incubation of nisin with high concentrations of
trypsin. Interestingly, nisin1-12 acts as an antagonist of the
antimicrobial activity of the wild-type peptide.116 It remains to
be clarified whether this truncated nisin molecule can compete
for binding at the cytoplasmic membrane, or competes in
Fig. 5 Primary structure of nisin Z showing the position of some site-directed mutations that have been introduced. Sites of proteolytic cleavage by trypsin
are indicated by dotted lines.
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another process of the nisin–membrane interaction, for instance
aggegation of nisin molecules. Alternatively, the fragment
might also inhibit the in vivo activity of nisin by competing for
binding to the putative docking molecule lipid II.
4.3 Insertion into membranes
Binding of nisin molecules to the surface of the cytoplasmic
membrane is assumed to be followed by insertion of the
peptides into the membrane. This insertion step appears to be an
essential step in the membrane permeabilizing effect of the
peptide and involves the penetration of (part of) the peptides
into the outer leaflet of the bilayer. To study the membrane-
insertion of nisin and nisin analogs, the lipid monolayer model
system has been used, which provides information on the
penetration of membrane-active peptides into the lipid layer,
while binding to the lipids is not reflected.117 Nisin efficiently
inserted into monolayers containing phosphatidylglycerol or
cardiolipin, whereas the interaction with zwitterionic lipids was
significantly lower. For mutant nisin species, particularly those
that contain N-terminal modifications, a good correlation was
found between the interaction with anionic monolayers and the
antimicrobial activity against Micrococcus flavus.117 The effect
of C-terminal modifications of nisin as in V32E nisin Z114 and
nisin Z-Asp-His6118 on membrane insertion was less pro-
nounced. From these results it was concluded that the
monolayer data predominantly reflect the membrane insertion
of the N-terminal region, and that the C-terminal part of nisin
contributes to a lesser extent to the process of membrane
insertion.
4.4 The orientation of nisin in membranes
Studies of the nisin–membrane interaction at the molecular
level have shown that the molecules have an orientation that is
parallel to the surface of the membrane. NMR spectroscopic
studies on nisin complexed to membrane-mimicking micelles
showed that the peptides are located at the surface of these
micelles, such that the hydrophobic sites are immersed below
the surface, while the more polar or charged residues have an
outward orientation.119,120 More recently, tryptophan fluore-
sence spectroscopy was applied to determine the topology of
nisin at the surface of a lipid bilayer.121 Since nisin does not
naturally contain Trp residues, tryptophan-containing variants
of nisin were developed by protein engineering techniques.92,101
Fluoresence studies on three Trp-mutants of nisin Z, containing
a unique Trp residue either at position 1, 17 or 32, indicated a
parallel orientation of the molecule with respect to the
membrane surface, similar to what was found for the micellar
systems.121 By using spin-labelled lipids, the insertion depth of
the different tryptophan residues in the lipid bilayer could be
determined, and revealed that all three tryptophans were
embedded in the hydrophobic part of the bilayer. The results
were in good agreement with that of a fluorescence quenching
study with the mutant Ile30Trp nisin A.122 The calculated
insertion depths of the different tryptophan residues and the data
of the NMR structure of nisin at the surface of micelles were
used to model the orientation of nisin at the membrane surface.
The results indicate that the molecule is inserted in the bilayer
in an overall parallel orientation with respect to the bilayer
surface, with the N-terminal part inserted slightly deeper than
the C-terminal part.121
The insertion of peptides at the cis-site of the membrane–
water interface is most likely not directly responsible for the
permeabilising effect of nisin, as has been proposed for the
mechanism of action of melittin and several other membrane-
active peptides.123 In contrast, it has been shown that the C-
terminal part of nisin translocates across the membrane, a
process that appears to be related to the membrane-per-
meabilizing activity of the peptide.118 This was demonstrated
by using an engineered nisin Z molecule, containing the C-
terminal extension Asp-His6 (His-tag-nisin Z). Addition of this
peptide to large unilamellar vesicles, which had trypsin
encapsulated in the lumen, resulted in proteolytic cleavage of
the C-terminal extension from part of the peptides. From these
results it was concluded that the C-terminal part of these
peptides was at least temporarily exposed to the vesicle lumen.
The translocation process was proposed to be an essential step
in the pore-forming mechanism of nisin. It was observed that
complexing the C-terminal histidine residues with nickel ions or
increasing the positive charge of the histidines by lowering the
pH, resulted in blocking of the translocation process, and
concomitantly the permeabilizing capacity of the peptide was
strongly decreased. The interpretation of these results was that
the formation of bulky Ni–histidine complexes or the presence
of strong electrostatic interactions leads to anchoring of the C-
terminus at the membrane surface, which prohibits the trans-
location of this region across the membrane.118 The results
further suggest that for the membrane permeabilizing activity of
nisin, at least in vesicles consisting solely of phospholipids, the
molecules have at some point in time a transbilayer orientation.
In view of the results of the tryptophan fluorescence experi-
ments it is considered unlikely that the nisin molecules exist in
a stable transmembrane orientation, as has been proposed for
the pore-forming peptide alamethicin.123
4.5 Permeabilisation of membranes
The membrane-permeabilising activity of lantibiotics has been
extensively studied on intact bacterial cells, protoplasts,
liposomes, proteoliposomes and black lipid membranes. The
results of the in vivo and in vitro experiments are all consistent
with the conclusion that lantibiotics induce efflux of low
molecular weight compounds and a rapid dissipation of the
proton motive force.113–116,24,125 For an overview of these
studies the reader is referred to Moll et al.126 The addition of
nisin to liposomes results in a rapid release of the entrapped
solutes. The nisin-induced leakage is initially fast and levels off
in time. A comparison of the nisin-induced release of potassium
and carboxyfluorescein revealed that the rate and extent of
carboxyfluorescein leakage is higher, suggesting that the pores
are to some extent anion-selective.114 This suggestion was
supported by the results of planar membrane studies, showing
that the replacement of residue Lys-12 by an uncharged Leu in
nisin A resulted in a strongly increased membrane conductance,
which indicated that due to the removal of the charged Lys-12
increased passage of ions through the nisin pore was al-
lowed.115
The presence of anionic lipids is a prerequisite for the pore-
forming activity of nisin, as was demonstrated in model
membrane systems, such as liposomes,113,114 lipid mono-
layers114,119 and planar lipid membranes115,124 as well as in
bacterial membrane systems.114 In contrast, the permeabilizing
activity of nisin on liposomes composed of zwitterionic lipids is
very low. It has been suggested that nisin acts as an anion-
carrier on these vesicles, such that it translocates across the
membrane, binds anionic compounds at the inside, and
subsequently translocates back to the outer surface, where the
anion is released.107 However, negatively charged lipids were
shown to inhibit this process, and therefore the anion-carrier
activity is expected to be low in vivo.107
Several studies have demonstrated that the presence of a
transmembrane electrical potential (Dy) or pH gradient (DpH)
is not essential for nisin activity, since in the absence of a Dy,
nisin effectively induced permeabilisation of liposomes and
bacterial membranes.113,114,116,120,123,124 However, upon the
imposition of a Dy (negative inside), the membrane-disruptive
activity of nisin in model membrane systems and in bacterial
membranes was increased.114,127,128 Measurements on sensitive
Lactococcus lactis cells and proteoliposomes, using fluorescent
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pH-indicators, revealed that the nisin activity also increases
with the magnitude of the DpH (inside alkaline).116 The role of
both these components of the proton motive force in the
molecular mechanism of action of nisin is still unclear. No
effect of the Dy was observed on binding affinity of nisin for
the membrane,114 or on the orientation of nisin at the membrane
surface.123 Possibly, the Dy and DpH act on the membrane-
associated nisin molecules by promoting a switch from a
parallel orientation into a membrane-spanning orientation. An
inside-negative electrochemical potential might accelerate the
translocation of the positively charged C-terminal part of the
peptide across the membrane.
It is likely that the pore-forming activity of lantibiotics
involves the aggregation of several peptides. Since lantibiotics
have a length of approximately 5 nm, they can span the
membrane only once and therefore it can be excluded that a
membrane channel is formed by a single molecule. Indications
for a possible aggregation process were obtained in binding
studies of nisin to liposomes.114 and planar lipid bilayer
studies.125 However, aggregates of nisin have not been detected
so far. An explanation for this could be that only a minor
fraction of the peptides is involved in aggregation, or that the
aggregates are short-lived, and therefore difficult to trap. Single
channel recordings in planar membrane experiments indicated
that lantibiotics form transient channels with a lifetime in the
order of milliseconds.129 The diameter of the channels was
calculated to be 0.2–1 nm. Different conductance levels were
observed with nisin, indicating that pore complexes with
varying numbers of participitating molecules are formed,
resulting in variable pore diameters. Similar results were
obtained with the lantibiotics Pep5,130 subtilin131 and strepto-
coccin A-FF22.132
4.6 Model for the mode of action of lantibiotics
Several models have been proposed to explain the membrane-
activity of nisin. Most of the models are based on the ‘barrel-
stave’ model, initially proposed for nisin by Sahl et al.133,134 In
current models it is assumed that nisin, in particular the C-
terminal region of the molecule, binds to anionic phospholipids
by means of electrostatic interactions (Fig. 6, step 1). In vivo, the
binding of nisin and epidermin to bacterial membranes might
also involve the interaction with the peptidoglycan precursor
lipid II. This more specific interaction was suggested to be
mediated by the N-terminal part of nisin, as nisin and epidermin
share a homologous N-terminal ring pattern. The membrane-
associated peptides, or at least part of them, insert into the
membrane, thereby taking an orientation parallel to the
membrane surface.121–123 (step 2). The hydrophobic residues of
nisin interact with the fatty acyl chains of the lipids, while the
polar residues are located at the membrane–water interface.
According to the barrel-stave model, the peptides subsequently
switch into a membrane-spanning orientation (step 3), and form
a cluster around a central water-filled pore (step 4a). It is likely
that this process is preceeded by aggregation of peptides,
although this process remains speculative. In an alternative so-
called ‘wedge-model’ it was proposed that the bound anionic
lipids co-insert with the peptide, resulting in bending of the lipid
surface, giving rise to wedge-like pores114 (step 4b). Both
models assume that nisin exposes its charged residues to the
lumen of the pore, which is expected to result in anion
selectivity of the nisin pore. It has been proposed that the C-
terminal region of the peptides switches across the membrane to
form a pore.120 Possibly, the electrochemical membrane
gradient facilitates this process, by pulling the charged C-
terminus across the membrane. The transmembrane orientation
of the peptides is presumably only transient. Upon disassembly
of the pores, the peptides are assumed to flip back to an
orientation parallel to the membrane surface. Since the
concentration of nisin molecules in the outer leaflet of the
membrane is high, peptides could flip to the inner leaflet of the
membrane, similar to the mechanism of action proposed for the
a-helical peptides magainin, mastoporan and melittin.135
5 Applications and prospects
Ever since the discovery of the first member of the lantibiotics,
nisin A, the application of these antimicrobial peptides has
received considerable attention. Presently both type A and type
B lantibiotics are used in agricultural, veterinary and medical
practice and, more recently, also in personal care products
(Table 2). Important factors that underlie the application of
lantibiotics include a desired antimicrobial efficiency, such as
indicated by minimal inhibitory concentrations and spectrum as
discussed above, appropriate stability, and cost-effective pro-
duction level. Moreover, several lantibiotics are produced by
bacteria that have a long history of safe use in foods which allow
these to be applied in food products. Below an overview is given
of the different lantibiotics that have reached the stage of
application, have potential to become applied, or have specific
prospects that are relevant to discuss with respect to their
application in pharma or food (Table 2).
5.1 Pharmaceutical applications
While food applications are limited to type A lantibiotics that
are produced by food-grade bacteria, both type A and type B
Fig. 6 Model for the mechanism of action of nisin. At first nisin binds to the
surface of the membrane (1), followed by insertion of the molecule into the
membrane (2). The peptides switch to a membrane spanning orientation,
involving translocation of the C-terminus of the peptides across the
membrane (3). A transmembrane aqueous pore is formed, most likely
consisting of several peptides (4). Membrane phospholipids might co-insert,
resulting in bending of the lipid surface (4b).
Table 2 Overview of present and potential future applications of several
type-A and type-B lantibiotics
Present or future applications
Lantibiotics Food Medical Veterinary Personal care
Nisin A / Z 3 3 3 3
Epidermin/Gallidermin 3 3
Lacticin 481 / Variacin 3
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lantibiotics are used in pharmaceutical applications (Table 2). In
fact the first applications of nisin were ventured in clinical and
veterinary therapies.136 However, the intravenous use of nisin
has not been further developed since nisin shows a low stability
at physiological pH. However, several protein-engineered
derivatives of nisin Z have been generated in recent years that
show improved stability and these or others may extend the
medical application of nisin.93,137 Various alternative pharma-
ceutical applications of nisin have been considered. One that
builds on the high activity at low pH relates to the use of nisin
to antagonize Helicobacter pylori which is the causative agent
of gastric ulcers.138 Since this is a high value market, it is
feasible that the development of specific nisin species that have
been improved by protein engineering could be rewarding. The
same holds for the use of nisin to inhibit growth of multidrug-
resistant pathogens. In a recent survey, the capacity of nisin to
prevent growth of resistant Staphylococcus aureus or Strepto-
coccus pneumoniae was found to be promising, although
resistance development was observed.139 Another application is
the use of nisin as a sanitizer against mastitis pathogens in cows
that also include Streptococcus and Staphylococcus spp.140
Finally, the use of nisin in personal-care products such as mouth
wash or deodorants has also been suggested.
Pharmaceutical applications of other lantibiotics are limited
and include mersacidin and the related peptides gallidermin and
epidermin. Mersacidin is produced by a Bacillus subtilis strain
and inhibits the cell wall synthesis of methicillin-resistant
staphylococci with a similar efficiency to vancomycin.141
However, its mode of action differs from vancomycin which
allows combination with this important last option antibiotic.142
The lantibiotics epidermin and gallidermin that are produced by
the related Staphylcoccus epidermidis and gallinarum, re-
spectively, and differ in a single residue, have been tested in
medical and personal care products. These lantibiotics show
activity against Propionibacterium acnei, the causative agent of
juvenile acne.16 In addition, they have antagonistic activity
against staphylococci and streptococci isolated from skin and
hence have been implied in deodorants. Recently, several
mutants of gallidermin have been described that have improved
antimicrobial activity and these may have potential since the
efficiency of this lantibiotic is not so high as that of nisin.143
The type B lantibiotics exclusively have pharmaceutical
potential and the lantibiotics duramycin (including duramycin B
and C) and cinnamycin were found to inhibit phospholipase A2.
This enzyme plays a major role in the release of arachidonic
acid from phospholipids that may be oxidized resulting in the
formation of prostaglandins and leukotrienes, both potent
promoters of inflammations and allergies. As a consequence,
the lantibiotics duramycin and cinnamycin have potential as
antiinflammatory drugs. Their mode of action has been shown
to involve inhibition of phospholipase A2 indirectly by
sequestering the substrate phosphatidylethanolamine, analo-
gous to the protein lipocortin.144 The other type B lantibiotic
with medical application is ancovenin that has reported to be an
inhibitor of the angiotensin converting enzyme and hence can
be used to treat high blood pressure.16
5.2 Food applications
Many applications concern the use of nisin, not only for
historical reasons, since this lantibiotic couples a high anti-
microbial efficiency to a wide host-range including vegetative
cells and spores of many Gram-positive bacteria that are either
pathogenic or otherwise undesired. Since they only differ in the
solubility at neutral pH values, the applications of the two
natural variants of nisin, nisin A and nisin Z, are discussed here
simultaneously, although superiority of nisin Z in some
applications is to be expected.145 The fact that the solubility of
nisin improves at low pH has been exploited in the use of nisin
in acidified food products. These applications were facilitated
by the fact that the production host of nisin belongs to the
species Lactococcus lactis, strains of which are used as starter
cultures for industrial cheese fermentations. Notably, the use of
nisin-producing strains to control the outgrowth of spores of the
cheese-spoilage bacterium Clostridium tyrobutryricum ap-
peared to be a promising application and has been followed by
many others, including control of Clostridium botulinum and
other pathogens in processed or canned foods.146 The observa-
tion that the property to produce nisin could be transferred to
specific industrial L. lactis strains by conjugation, since the nis
gene cluster is located on so-called conjugative transposons,
further enhanced the applications of nisin-producing
strains.147,148 Another development that has contributed to the
expanded use of nisin is the finding that its antimicrobial
activity and spectrum can be enhanced by the addition of several
compounds. A prominent synergistic activity is observed when
divalent cations are eliminated by the use of chelating agents
such as EDTA or citrate, thus destabilizing the outer membrane
of Gram-negative bacteria that hence become sensitive to
nisin.105 Remarkably, not only Gram-negative bacteria, which
include many pathogens, may thus become sensitized to nisin,
but also yeast cells may become sensitive to nisin when devoid
of their cell wall, although high doses are required.149 In
addition, several other compounds, such as magainin II amide
or sucrose fatty esters, have been found to enhance the
antimicrobial activity of nisin against relevant pathogens.150,151
Finally, synergistic activities of nisin and other antimicrobial
peptides, including the lantibiotic lacticin 481, has been
reported.152 Presently, nisin is used world-wide as a food
preservative and is by far the most widely applied lantibiotic. It
is used in more than 50 different countries in products ranging
from processed cheese to salad dressings and bread to beer,
wine, and other alcoholic drinks.138 Some of the applications of
nisin, however, are jeopardized since the use of antimicrobials
in foods is presently under political pressure. Nonetheless, it
should be noted that there has not been any indication of cross-
resistance to clinically relevant antibiotics nor any sign of nisin-
resistant pathogens.
Various other lantibiotics couple production by food-grade
hosts to high antimicrobial activity to relevant pathogens or
food-spoilage organisms. These include lacticin 481 produced
by Lactococcus lactis153 and the highly homologous lantibiotic
variacin, produced by the meat starter Micrococcus varians.35
The recently discovered antimicrobial peptide lacticin 3147 has
a high activity against Listeria spp. Although evidence for the
presence of lanthionine residues in lacticin 3147 has not been
provided yet, the genetic information on its structural gene and
flanking sequences which are located on a fully sequenced
plasmid, strongly argues for the presence of the post-transla-
tional modifications found in lantibiotics.18 Since this plasmid
can be conjugationally transferred to other L. lactis strains,
similar strategies as with nisin-producing strains are feasible
and the use of lacticin 3147 transconjugants as alternative
salami starters has been documented.154
Presently, no lantibiotics that have been improved by protein
engineering are applied in foods but the future use of nisin
mutants with improved antimicrobial efficiency remains a
realistic option for specific applications.155
6 Concluding remarks
Investigations into a wide range of lantibiotics and their
producing organisms have demonstrated an enormous progress
in the lantibiotic field. In the last five years, great advances have
been made in studies on production, biological activity and
applications of lantibiotics. Still, fundamental questions remain
to be answered in the field. The mechanism by which
lantibiotics are post-translationally modified and the role of the
proteins LanB, C, M, D and O in these processes is still unclear.
Further insight into this subject could extend the possibilities for
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mutagenesis of lantibiotics, since currently biosynthetic prob-
lems are encountered with the production of many mutant
peptides. Also, unraveling of the mechanism by which the
immunity proteins LanI, F, E and G protect the producing cell
from the bacteriocidal activity is a great scientific challenge,
since this mechanism is very poorly understood. The use of site-
directed mutants to study structure–function relationships and
the mode of action of lantibiotics has proven to be valuable.
Great progress was made in elucidation of the molecular
mechanism of action of lantibiotics. Future studies will continue
to be directed towards understanding of the interaction of the
peptides with target membranes and unraveling of the pore
complex. Another great challenge arises from the recent
findings that some lantibiotics specifically interact with a
docking molecule, present at the outside of target cells. This
fascinating topic is currently under further investigation.
Possibly, these studies will improve insight into the factors that
determine sensitivity of bacteria to lantibiotics. As indicated in
the last section of this review broader applications of lanti-
biotics are to be expected in the future. Regarding this, more
insight into the development of resistance by undesired
organisms will be required. Also, a better stability and
effectiveness of lantibiotics in biological systems should be
realized, which could for instance be accomplished by protein
engineering of lantibiotics and by searching for new synergistic
combinations with other compounds.
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